Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,743 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-11 · Sale · Disposed 22,417 · Balance 51,326 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Row 2 · 2026-06-12 · Sale · Disposed 12,583 · Balance 38,743 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apogee Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Disposition to issuer · Disposed 1,375 · Balance 167,123 Row 2 · 2026-09-03 · Disposition to issuer · Disposed 167,123 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 110,665 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 124,962 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-03 · Disposition to issuer · Disposed 83,690 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 10, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,025 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-26-002574 · tm262641-1_4seq1.xml · derivative · entry 6 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,540 Underlying: Common Stock · 14,025 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 100 | $80.06 | $8,006.00 |
DisclosureSEC source: 0001104659-26-002574 · tm262641-1_4seq1.xml · nonDerivative · entry 5 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,523 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 826 | $79.04 | $65,287.04 |
DisclosureSEC source: 0001104659-26-002574 · tm262641-1_4seq1.xml · nonDerivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,623 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.70 to $79.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 14,820 | $77.90 | $1,154,478.00 |
DisclosureSEC source: 0001104659-26-002574 · tm262641-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,449 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.45 to $78.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,954 | $77.13 | $227,842.02 |
DisclosureSEC source: 0001104659-26-002574 · tm262641-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 228,269 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $76.44 to $77.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 14,025 | $22.86 | $320,611.50 |
DisclosureSEC source: 0001104659-26-002574 · tm262641-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Due to an administrative error, the amount reported in Column 5 on the reporting person's Form 4 filed on October 3, 2025 was overstated by 53,910 shares. As a result, the beneficial ownership totals reported in the reporting person's Forms 4 filed after October 3, 2025 were each overstated by 53,910 shares. This Form 4 reflects the correct amount of common stock beneficially owned by the reporting person. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:03 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 83,690 | $0.00 Strike: $75.78 | $0.00 |
DisclosureSEC source: 0001104659-26-001485 · tm261906-2_4seq1.xml · derivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,690 Underlying: Common Stock · 83,690 shares Expires 2036-01-02 F1 · derivative.exercise_date: This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:03 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 10,900 | $75.00 | $817,500.00 |
DisclosureSEC source: 0001104659-25-118986 · tm2532835-3_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,108 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.00 to $75.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 05, 2025 Filed Nov 8, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,060 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · derivative · entry 6 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,565 Underlying: Common Stock · 8,060 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 05, 2025 Filed Nov 8, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 678 | $56.51 | $38,313.78 |
DisclosureSEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 5 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,008 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.31 to $56.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 05, 2025 Filed Nov 8, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 5,607 | $55.58 | $311,637.06 |
DisclosureSEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,686 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.25 to $56.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 05, 2025 Filed Nov 8, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,200 | $54.83 | $120,626.00 |
DisclosureSEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,293 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.24 to $55.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 05, 2025 Filed Nov 8, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,300 | $53.62 | $123,326.00 |
DisclosureSEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 290,493 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $53.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 05, 2025 Filed Nov 8, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 8,060 | $22.86 | $184,251.60 |
DisclosureSEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2025 Filed Oct 4, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,385 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-25-096792 · tm2527919-1_4seq1.xml · derivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,625 Underlying: Common Stock · 2,385 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 01, 2025 Filed Oct 4, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 5,110 | $39.80 | $203,378.00 |
DisclosureSEC source: 0001104659-25-096792 · tm2527919-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,733 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.33 to $40.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2025 Filed Oct 4, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 2,385 | $22.86 | $54,521.10 |
DisclosureSEC source: 0001104659-25-096792 · tm2527919-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 6, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 190 | $38.55 | $7,324.50 |
DisclosureSEC source: 0001104659-25-087939 · tm2525198-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,548 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $38.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 03, 2025 Filed Sep 6, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,535 | $37.82 | $95,873.70 |
DisclosureSEC source: 0001104659-25-087939 · tm2525198-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,738 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.39 to $38.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,725 | $37.78 | $102,950.50 |
DisclosureSEC source: 0001104659-25-075801 · tm2522902-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,273 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. Read SEC document |
| July 02, 2025 Filed Jul 4, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,365 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · derivative · entry 5 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,010 Underlying: Common Stock · 7,365 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 02, 2025 Filed Jul 4, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 746 | $46.26 | $34,509.96 |
DisclosureSEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · nonDerivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,998 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.16 to $46.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 02, 2025 Filed Jul 4, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,935 | $45.49 | $133,513.15 |
DisclosureSEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,744 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.14 to $46.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 02, 2025 Filed Jul 4, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 6,409 | $44.77 | $286,930.93 |
DisclosureSEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,679 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 02, 2025 Filed Jul 4, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 7,365 | $22.86 | $168,363.90 |
DisclosureSEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 249,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2025 Filed Jun 7, 2025 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,725 | $36.96 | $100,716.00 |
DisclosureSEC source: 0001104659-25-057468 · tm2517306-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,723 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:13 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $11.77 | $0.00 |
DisclosureSEC source: 0001062993-25-010825 · form4.xml · derivative · entry 1 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-06-01 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 2, 2025. Read SEC document |
| May 07, 2025 Filed May 10, 2025 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,725 | $35.75 | $97,418.75 |
DisclosureSEC source: 0001104659-25-046896 · tm2514565-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,448 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.23 to $36.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 889 | $37.59 | $33,417.51 |
DisclosureSEC source: 0001104659-25-032308 · tm2511489-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,173 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.34 to $37.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 500 | $37.03 | $18,515.00 |
DisclosureSEC source: 0001104659-25-032308 · tm2511489-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,062 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.32 to $37.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,471 | $35.56 | $87,868.76 |
DisclosureSEC source: 0001104659-25-032308 · tm2511489-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,562 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.09 to $36.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,590 | $30.48 | $48,463.20 |
DisclosureSEC source: 0001104659-25-021862 · tm258443-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 251,033 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 795 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-25-010645 · tm255633-2_4seq1.xml · derivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,375 Underlying: Common Stock · 795 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 3,520 | $40.69 | $143,228.80 |
DisclosureSEC source: 0001104659-25-010645 · tm255633-2_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 252,623 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.42 to $41.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 795 | $22.86 | $18,173.70 |
DisclosureSEC source: 0001104659-25-010645 · tm255633-2_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,360 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · derivative · entry 5 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,170 Underlying: Common Stock · 1,360 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 100 | $47.92 | $4,792.00 |
DisclosureSEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · nonDerivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,348 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,486 | $47.21 | $117,364.06 |
DisclosureSEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,448 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.88 to $47.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,499 | $46.42 | $69,583.58 |
DisclosureSEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 257,934 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.87 to $46.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 1,360 | $22.86 | $31,089.60 |
DisclosureSEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,815 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-24-128559 · tm2430955-1_4seq1.xml · derivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,530 Underlying: Common Stock · 1,815 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 455 | $50.00 | $22,750.00 |
DisclosureSEC source: 0001104659-24-128559 · tm2430955-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 258,073 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 4,085 | $48.62 | $198,612.70 |
DisclosureSEC source: 0001104659-24-128559 · tm2430955-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 258,528 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 1,815 | $22.86 | $41,490.90 |
DisclosureSEC source: 0001104659-24-128559 · tm2430955-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2024 Filed Dec 12, 2024 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 124,962 | $0.00 Strike: $49.07 | $0.00 |
DisclosureSEC source: 0001104659-24-127704 · tm2430773-1_4seq1.xml · derivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,962 Underlying: Common Stock · 124,962 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option represents the right to purchase 124,962 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 04, 2024 Filed Dec 7, 2024 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 6,665 | $46.07 | $307,056.55 |
DisclosureSEC source: 0001104659-24-126395 · tm2430233-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,798 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. Read SEC document |
| November 06, 2024 Filed Nov 9, 2024 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,339 | $59.96 | $80,286.44 |
DisclosureSEC source: 0001104659-24-116027 · tm2427837-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,463 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.55 to $60.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 06, 2024 Filed Nov 9, 2024 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 5,326 | $58.91 | $313,754.66 |
DisclosureSEC source: 0001104659-24-116027 · tm2427837-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,802 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.50 to $59.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 02, 2024 Filed Oct 5, 2024 00:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 925 | $56.86 | $52,595.50 |
DisclosureSEC source: 0001104659-24-106367 · tm2425574-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,128 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.64 to $57.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 02, 2024 Filed Oct 5, 2024 00:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 5,740 | $56.16 | $322,358.40 |
DisclosureSEC source: 0001104659-24-106367 · tm2425574-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,053 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.62 to $56.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.